N/A N=513 Comparison of Contrast Agents During CT Angiography
Contrast Enhancement on Cardiac CT
Primary: Image Quality of the CT Scans Using Different Contrast Agents — 333; 357; 362; 288 hounsfield units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=299 Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
Patient Comfort and Safety
Primary: Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis. — 53; 99 Number of…
N/A N=900 Uniformity of Oral Contrast Material in the Bowel
Known or Suspected Abdominal Disease
Primary: Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging — 140; 73; 68 Participants
Phase 4 N=100 Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Coronary Artery Disease
Primary: Thrombin Generation Test: Baseline — 1810; 1682 nM*minutes
Phase 3 N=33 Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
Coronary Computed Tomographic Angiography
Primary: Contrast to Noise Ratio — 18.6; 20.5 CNR
Phase 4 N=150 Thoracoabdominal Arortic CTA Study
Thoracic Aortic Aneurysm
Primary: Radiation Dose — 35.1; 25.4; 25.5 mSv
N/A N=96 DyeVert System RCT
Coronary Angiography
Primary: Evaluate the Total Volume of CM Used Comparing the DyeVert Group to the Control Group. — 38.0; 62.5 ml
Phase 4 N=122 Contrast Nephropathy and Nitrates
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Phase 4 N=255 Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
Drug Safety
Primary: Subjects Experiencing Discomfort When Undergoing Peripheral Arteriography — 53; 92; 48; 82 participants
Phase 4 N=468 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
Coronary Artery Disease
Primary: Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading Assessment — 92.1; 95.4; 94.6 Percentage…
N/A N=23 Optical Imaging Measurement of Intravascular Solution Efficacy Trial
Peripheral Artery Disease
Primary: Quality of Images — .702; .872; .10; .743 Clear imaging field (CIF) proportion
N/A N=89 Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion
Breast Carcinoma · Invasive Breast Carcinoma
Primary: Accuracy of CEM for Incremental Cancer Detection in the Ipsilateral and Contralateral Breasts. — 41.4 % of malignancy in new CEM lesions
Phase 4 N=300 Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
Healthy
Primary: Preferred Contrast Agent — 25; 29; 117; 116 participants — p=<0.001
N/A N=166 Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media
Diabetes Mellitus · Lactic Acidosis
Primary: Incidence of Lactic Acidosis — 0; 0 participants
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Phase 4 N=615 Screening Contrast-Enhanced Mammography as an Alternative to MRI
Breast Cancer
Primary: Cancer Detection Rate (CDR) Per 1,000 Screenings — 8.3; 18.3 CDR per 1,000 screenings
N/A N=578 AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
Contrast Induced Nephropathy (CIN)
Primary: Primary Effectiveness Endpoint — 76; 75 Participants
N/A N=114 DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Chronic Kidney Disease
Primary: Percentage of Contrast Media Volume Saved — 40.1 % CMV savings per procedure
Phase 4 N=83 IVUS Guidance to Reduce Contrast in Coronary Angioplasty
Contrast Media Reaction · Acute Renal Failure
Primary: Total Volume of Iodine Contrast Used During Procedure — 64.5; 20.0 ml
Phase 3 N=434 Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
Computed Tomography · Diagnostic Imaging
Primary: The Quality of Visualization of the Contrast-Enhanced Computed Tomography (CECT) Images, Based on the Blinded Readers' Assessment. — 366; 17; 16; 3 Number of…
Phase 4 N=49 Kidney Damage in Patients With Normal eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media. — -14.84; -17.71; -9.98; -2.37 ng/mL
N/A N=8 Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Liver Neoplasms
Primary: Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography — 8 tumor
Phase 2 N=271 Sodium Chloride and Contrast Nephropathy
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
N/A N=11 Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Kidney Cancer
Primary: Successful Capture of IO-CEUS Images — 10 participants
N/A N=238 Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans
Contrast Enhanced Computed Tomography
Primary: Acceptable Image Quality — 100; 100; 100 percentage of participants
Phase 4 N=132 Renal Safety Evaluation After Dotarem®-Enhanced MRI
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
N/A N=67 A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Breast Cancer
Primary: Number of Participants With Technical Success — 60 Participants
Phase 2 N=191 Coronary MDCTA With Iopamidol Injection 370
Coronary Artery Disease
Primary: Diagnostic Quality of Visualization of Coronary Arteries, Off-Site Reader 1 — 949; 842; 841 Segments Visualized Accurately — p=0.0099
Phase 4 N=17 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
Pediatric Congenital Heart Disease
Primary: Composite Image Quality Score Among 7 Anatomical Structures. — 3.9; 2.7 score on a scale
Phase 2 N=50 Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)
Healthy
Primary: Blood Urea Nitrogen and Creatinine Serum Values — 12.3; 14.7; 14.5; 12.8 mg/dL